300086 康芝药业
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-9.4580.867-13.3030.7310.620
总资产报酬率 ROA (%)-5.7710.518-7.9030.4330.389
投入资产回报率 ROIC (%)-6.5820.588-8.9460.4980.464

边际利润分析
销售毛利率 (%)53.45660.00750.79650.45751.304
营业利润率 (%)-38.6363.378-39.8342.5576.295
息税前利润/营业总收入 (%)-34.9076.218-36.6934.6004.736
净利润/营业总收入 (%)-34.2630.699-36.9491.2642.169

收益指标分析
经营活动净收益/利润总额(%)112.087146.64169.002-30.263223.310
价值变动净收益/利润总额(%)-11.870-49.4788.689290.21238.738
营业外收支净额/利润总额(%)0.951-6.5583.661-5.075-101.742

偿债能力分析
流动比率 (X)1.0981.6011.3291.4851.221
速动比率 (X)0.6330.9800.9911.0770.859
资产负债率 (%)38.57736.36840.76836.8130.387
带息债务/全部投入资本 (%)27.42824.55030.93126.95528.317
股东权益/带息债务 (%)248.015289.663209.659257.840236.372
股东权益/负债合计 (%)155.289170.741141.076166.157148.475
利息保障倍数 (X)-8.5152.040-7.8832.1232.931

营运能力分析
应收账款周转天数 (天)74.04150.38274.09263.48848.145
存货周转天数 (天)365.014247.588251.465177.116152.603